Edwin M. Kilbourne, MD; Leslie A. Swygert, MD; Rossanne M. Philen, MD; Richard K. Sun, MD, MPH; Steven B. Auerbach, MD, MPH; Lynn Miller, DVM, MPH; David E. Nelson, MD, MPH; Henry Falk, MD, MPH
This content is PDF only. Please click on the PDF icon to access.
The Centers for Disease Control (CDC) has recently received a large volume of calls from physicians caring for patients with either clear-cut or suspected cases of the eosinophilia-myalgia syndrome, an apparently new clinical entity recently recognized as having occurred in epidemic form over at least the last several months ( 1 ). Because this epidemic was only recognized late in 1989, factual information about the disease is still limited. Work directed toward determining the full spectrum of clinical manifestations is still in progress, and optimal treatment and prognosis have not yet been determined.
The observations and recommendations set forth here
Kilbourne EM, Swygert LA, Philen RM, Sun RK, Auerbach SB, Miller L, et al. Interim Guidance on the Eosinophilia-Myalgia Syndrome. Ann Intern Med. 1990;112:85–87. doi: 10.7326/0003-4819-112-2-85
Download citation file:
Published: Ann Intern Med. 1990;112(2):85-87.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use